{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=17&sponsor=Sanofi",
    "query": {
      "sponsor": "Sanofi",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1768,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=18&sponsor=Sanofi&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=16&sponsor=Sanofi&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T17:43:15.322Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04154943",
      "title": "Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2020-03-10",
      "completion_date": "2025-11-19",
      "has_results": true,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 15,
      "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 11 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04154943"
    },
    {
      "nct_id": "NCT00174720",
      "title": "Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Ciclesonide (XRP1526)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 708,
      "start_date": "2005-09",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2009-04-08",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00174720"
    },
    {
      "nct_id": "NCT00366795",
      "title": "Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ascites",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Satavaptan",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2006-08",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2016-05-18",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 1,
      "location_summary": "Malvern, Pennsylvania",
      "locations": [
        {
          "city": "Malvern",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366795"
    },
    {
      "nct_id": "NCT00153881",
      "title": "Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Esophageal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Capecitabine (Xeloda)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2000-02",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-11-13",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00153881"
    },
    {
      "nct_id": "NCT05769777",
      "title": "Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis Atopic"
      ],
      "interventions": [
        {
          "name": "Amlitelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 999,
      "start_date": "2023-04-03",
      "completion_date": "2031-06-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Bryant, Arkansas + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05769777"
    },
    {
      "nct_id": "NCT00566657",
      "title": "Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Vascular Diseases"
      ],
      "interventions": [
        {
          "name": "riferminogene pecaplasmid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (for riferminogene pecaplasmid)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 525,
      "start_date": "2007-11",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2016-05-02",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00566657"
    },
    {
      "nct_id": "NCT00223665",
      "title": "Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Flutamide",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "21 Years and older · Male only"
      },
      "enrollment_count": 102,
      "start_date": "1997-01-08",
      "completion_date": "2012-09-06",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223665"
    },
    {
      "nct_id": "NCT00115375",
      "title": "Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Heart Defects",
        "Blood Platelet Disorders"
      ],
      "interventions": [
        {
          "name": "Clopidogrel (SR25990)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 92,
      "start_date": "2004-01",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2009-03-25",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00115375"
    },
    {
      "nct_id": "NCT03637764",
      "title": "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "Isatuximab SAR650984",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2018-08-06",
      "completion_date": "2022-05-11",
      "has_results": true,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 3,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03637764"
    },
    {
      "nct_id": "NCT00206700",
      "title": "Open-label Trial of Leukine in Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Sargramostim (Leukine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 378,
      "start_date": "2003-02",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-19T17:43:15.322Z",
      "location_count": 98,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206700"
    }
  ]
}